Can Roche's #1 Therapeutic Area With $28 Billion In Revenue Grow Further?

Roche Holding's (NASDAQ:RHHBY) oncology portfolio is its largest therapeutic area and it will likely remain flat with revenues of around $29 billion over the next few years, as growth in sales of newer drugs, such as Kadcyla, Tecentriq, and Alecensa will be offset by the decline expected in Mab...